A retrospective analysis was performed comparing the survival in 483 patients with advanced breast cancer during the period from 1962 to 1986. Recently, the five-year survival rate at the start of therapy to the primary tumor was 63% and the five-year survival rate after the recurrence was 25%. The survival has been significantly prolonged as opposed to the figure of less than 5% among patients of 15 years ago. Multidisciplinary treatment has been utilized as adjuvant and recurrent therapies, such as combined chemotherapy, chemo-endocrine therapy and irradiation. Within these patients, 13 cases (3%) survived for more than ten-years from recurrence. The patients were recurrent cases with a small amount of metastatic sites and responsive to long-term endocrine therapy.